Jones C D, Winter M A, Hirsch K S, Stamm N, Taylor H M, Holden H E, Davenport J D, Krumkalns E V, Suhr R G
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285.
J Med Chem. 1990 Jan;33(1):416-29. doi: 10.1021/jm00163a065.
The preparation and in vitro aromatase inhibitory activity of a wide variety of heterocyclic (4,4'-dichlorodiphenyl)methanes and -methanols are described. The choice of the two diaryl-bearing moieties as a vehicle for the evaluation of the heterocycles was made by the comparison of series of imidazole and pyridine-derived compounds with similar pyrimidine compounds reported previously. A structural model for the most active compounds is also presented. The activity of a related series of the compounds which contain two heterocyclic moieties was found to be consistent with the model. Many of the compounds evaluated, including representatives of the pyridine, imidazole, pyrimidine, pyrazole, triazole, thiazole, and isothiazole classes, exhibit EC50 potencies for aromatase inhibition at low nanomolar levels. These compounds are at least as potent as other nonsteroidal aromatase inhibitors reported previously.
描述了多种杂环(4,4'-二氯二苯基)甲烷和 - 甲醇的制备及其体外芳香酶抑制活性。通过将咪唑和吡啶衍生的系列化合物与先前报道的类似嘧啶化合物进行比较,选择了两个含二芳基的部分作为评估杂环的载体。还提出了最具活性化合物的结构模型。发现一系列含有两个杂环部分的相关化合物的活性与该模型一致。所评估的许多化合物,包括吡啶、咪唑、嘧啶、吡唑、三唑、噻唑和异噻唑类的代表物,在低纳摩尔水平下表现出对芳香酶抑制的EC50效力。这些化合物至少与先前报道的其他非甾体芳香酶抑制剂一样有效。